2hdl

Solution structure of Brak/CXCL14Solution structure of Brak/CXCL14

Structural highlights

2hdl is a 1 chain structure with sequence from Homo sapiens. Full experimental information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	Solution NMR, 20 models
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

CXL14_HUMAN Potent chemoattractant for neutrophils, and weaker for dendritic cells. Not chemotactic for T-cells, B-cells, monocytes, natural killer cells or granulocytes. Does not inhibit proliferation of myeloid progenitors in colony formation assays.^[1] ^[2]

Evolutionary Conservation

Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf.

Publication Abstract from PubMed

The chemokine CXCL14/BRAK participates in immune surveillance by recruiting dendritic cells. CXCL14 gene expression is altered in a number of cancers, but protein expression levels have not been investigated. Here we report that CXCL14 protein can be expressed in primary epithelial cells; however, in several immortalized and cancer cell lines this protein is targeted for polyubiquitylation and proteasomal degradation. We determined the NMR structure of CXCL14 to identify motifs controlling its expression. CXCL14 adopts the canonical chemokine tertiary fold but contains a unique five amino acid insertion (41VSRYR45) relative to other CXC chemokines. Deletion or substitution of key residues within this insertion prevented proteasomal degradation. Furthermore, we defined a 15 amino acid fragment of CXCL14 that is sufficient to induce proteasomal degradation. This study elucidates a post-translational mechanism for the loss of CXCL14 in cancer and a novel mode of chemokine regulation.

Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome.,Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR J Mol Biol. 2006 Nov 3;363(4):813-22. Epub 2006 Aug 26. PMID:16987528^[3]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K 2nd, Azam M, Hou YH. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999 Feb 24;255(3):703-6. PMID:10049774 doi:http://dx.doi.org/10.1006/bbrc.1999.0257
↑ Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, Ma S, Yu Y, Chen G. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol. 2000 Sep 1;165(5):2588-95. PMID:10946286
↑ Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome. J Mol Biol. 2006 Nov 3;363(4):813-22. Epub 2006 Aug 26. PMID:16987528 doi:http://dx.doi.org/10.1016/j.jmb.2006.08.057

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

[1] Hromas R, Broxmeyer HE, Kim C, Nakshatri H, Christopherson K 2nd, Azam M, Hou YH. Cloning of BRAK, a novel divergent CXC chemokine preferentially expressed in normal versus malignant cells. Biochem Biophys Res Commun. 1999 Feb 24;255(3):703-6. PMID:10049774 doi:http://dx.doi.org/10.1006/bbrc.1999.0257

[2] Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, Ma S, Yu Y, Chen G. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol. 2000 Sep 1;165(5):2588-95. PMID:10946286

[3] Peterson FC, Thorpe JA, Harder AG, Volkman BF, Schwarze SR. Structural determinants involved in the regulation of CXCL14/BRAK expression by the 26 S proteasome. J Mol Biol. 2006 Nov 3;363(4):813-22. Epub 2006 Aug 26. PMID:16987528 doi:http://dx.doi.org/10.1016/j.jmb.2006.08.057

[1]

[2]

[3]